Substance P
Also known as: H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2, Neurokinin A, Neurokinin SP, SP, Substance P, Substance P free acid, TAC1 peptide product
Source Substance P at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Substance P (SP) is an 11‑amino‑acid neuropeptide that modulates nociception, vascular tone and immune responses via NK1R activation. Primarily used as a research tool; not approved for therapeutic use.
Mechanism of Action
endogenous ligand for neurokinin‑1 (NK1) receptor; activates G‑protein signaling leading to pain transmission, vasodilation and inflammation
Routes of Administration
Goals & Uses
- Pain research / nociception modulationResearchHigh
- Depression / anxiety researchResearchModerate
- anti‑inflammatory modulationInflammationLow
- Wound healingDermatologicModerateTissue repair and wound healing
- Wound healing (investigational)Investigational TherapeuticLow
- Emesis / nausea researchResearchHigh
- AnalgesiaPain ManagementModerate
- Neurogenic inflammation characterizationResearchHigh
Contraindications
- Chronic pain conditions requiring stable managementPainModerate
- Severe hypotension or cardiovascular instabilityCardiovascularHigh
- Hypersensitivity to Substance P or tachykininsAllergyHigh
Adverse Effects
- HypotensionCardiovascularCommonLow blood pressure
- Nausea/vomitingGastrointestinalUncommon
- FlushingVascularCommonWarmth and redness of the skin
- Increased vascular permeability / edemaInflammatoryCommon
- Pain or burning at injection siteLocalCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- BronchoconstrictionRespiratoryUncommon
Drug Interactions
- Aprepitant / FosaprepitantHigh
- ACE inhibitors (e.g., captopril, enalapril)Moderate
- Neutral endopeptidase inhibitors (neprilysin inhibitors)Moderate
- Opioids (e.g., morphine)Low
Population Constraints
- Asthma / reactive airway diseasePulmonaryRelative
- PregnancyReproductive SafetyRelative
- Pediatric populationsAgeRelative
- Patients with inflammatory bowel diseaseGastrointestinalRelative
Regulatory Status
- European UnionUnapprovedNot authorized for clinical use
- United StatesUnapprovedInvestigational peptide only
- United KingdomUnapprovedResearch use only
Not approved by FDA, EMA, or MHRA as a therapeutic drug. Used extensively in preclinical and clinical research. NK1 receptor antagonists targeting the Substance P pathway are approved for chemotherapy-induced nausea and vomiting.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Substance P?
Substance P (SP) is an 11‑amino‑acid neuropeptide that modulates nociception, vascular tone and immune responses via NK1R activation. Primarily used as a research tool; not approved for therapeutic use.
What is Substance P used for?
Substance P is educationally associated with: Pain research / nociception modulation, Depression / anxiety research, anti‑inflammatory modulation, Wound healing, Wound healing (investigational), Emesis / nausea research, Analgesia, Neurogenic inflammation characterization. Educational only — not medical advice.
How is Substance P administered?
Recorded routes of administration: Intraarticular, Intradermal, Intranasal, Intrathecal, Intravenous, Topical.
What are the potential side effects of Substance P?
Reported adverse effects include: Hypotension, Nausea/vomiting, Flushing, Increased vascular permeability / edema, Pain or burning at injection site, Nausea, Bronchoconstriction. This list is not exhaustive — consult a qualified clinician.
Who should avoid Substance P?
Recorded contraindications: Chronic pain conditions requiring stable management, Severe hypotension or cardiovascular instability, Hypersensitivity to Substance P or tachykinins. Consult a qualified clinician before use.